ClinicalTrials.gg
CompletedNCT02947620Updated Jun 18, 2023

Metformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia (Phase 3)

A Phase 3 interventional study of Metformin/Atorvastatin 1500mg/40mg, QD and Metformin 1500mg, QD in Type II Diabetes and Dyslipidemia, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-06-18.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
185
Allocation
Randomized
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Diabetes Mellitus, Type 2 by Daewoong Pharmaceutical Co. LTD. — 6 open to participants now, 10 under way, 4 of them phase 3. Diabetes Mellitus, Type 2 · Daewoong Pharmaceutical Co. LTD..

Enrollment
7th of 16
185 · median 159
Started
2015
the only one that year
Phase 3
10 of 20
3 open now
Registered
1st of 20
by date

Among the 20 studies in Diabetes Mellitus, Type 2 by Daewoong Pharmaceutical Co. LTD., this one is the 7th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2015, is one of 10 in phase 3, and was the 1st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 20 studies in Diabetes Mellitus, Type 2 by Daewoong Pharmaceutical Co. LTD. are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Diabetes Mellitus, Type 2 by Daewoong Pharmaceutical Co. LTD., or all of them as a file.
02

Study summary

A Multi-center, Randomized, double-blind, active-controlled, phase 3 trial to evaluate the safety and efficacy of Metformin/Atorvastatin in subjects with Type II Diabetes and dyslipidemia.

03

Conditions studied

  • Type II Diabetes
  • Dyslipidemia
04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with Dyslipidemia and Type II Diabetes
  • 19 years later, men and women under the age of 80

Exclusion criteria

Exclusion Criteria:

  • Pregnant women, nursing mothers or subject who does not agree to assigned in the study
  • Subject with type I Diabetes
  • Subject with hypertension which does not controlled by treatment(have blood pressure > 180/110mmHg)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
185 participants (actual)

Study arms

  • Active comparator
    Metformin/Atorvastatin

    Metformin/Atorvastatin, QD

    Drug: Metformin/Atorvastatin 1500mg/40mg, QD

  • Placebo comparator
    Metformin

    Metformin, QD

    Drug: Atorvastatin 40mg, QD

  • Placebo comparator
    Atorvastatin

    Atorvastatin, QD

    Drug: Metformin 1500mg, QD

Interventions

  • DrugMetformin/Atorvastatin 1500mg/40mg, QD
  • DrugMetformin 1500mg, QD
  • DrugAtorvastatin 40mg, QD
06

What researchers measure

Primary outcomes

  1. Change in HbA1c

    Change in HbA1c after 16 weeks, relative to baseline, between the combination of Metformin 1500 mg and Atorvastatin 40 mg compared to Atorvastatin 40 mg alone

    Time frame: Change from baseline at 16 weeks

  2. Change in LDL Cholesterol

    Change in low-density lipoprotein cholesterol (LDL-C) after 16 weeks, relative to baseline, between Metformin 1500 mg alone and the combination of Metformin 1500 mg and Atorvastatin 40 mg

    Time frame: Change from baseline at 16 weeks

Secondary outcomes

  1. Change in LDL-C

    Change in LDL-C after 16 weeks, relative to baseline, between Atorvastatin 40 mg and the combination of Metformin 1500 mg and Atorvastatin 40 mg

    Time frame: Baseline and 16 weeks

  2. Change in HbA1c

    Change in HbA1c after 16 weeks, relative to baseline, between Metformin 1500 mg alone and the combination of Metformin 1500 mg and Atorvastatin 40 mg

    Time frame: Baseline and 16 weeks

  3. Percentage of subjects reaching the LDL-C treatment goal defined by the NCEP ATP III guideline (<100mg/dL) after 16 weeks of treatment with investigational products

    Time frame: 16 weeks

  4. Percentage of subjects reaching HbA1c <7.0% and <6.5% after 16 weeks of treatment with investigational products

    Time frame: 16 weeks

  5. Change in LDL-C and the associated rate of change after 4, 8, and 12 weeks of treatment with investigational products compared to baseline

    Time frame: Baseline, 4 weeks, 8 weeks and 12 weeks

  6. Change in LDL-C after 16 weeks, relative to baseline, in subjects treated with investigational products

    Time frame: Baseline and 16 weeks

  7. Change in lipid variables and the associated rate of change

    Change in lipid variables (HDL-C, TG, TC, non-HDL cholesterol, Apolipoprotein A1, Apolipoprotein B) and the associated rate of change after 4, 8, 12, and 16 weeks of treatment with investigational products compared to baseline

    Time frame: Baseline, 4 weeks, 8 weeks and 12 weeks and 16 weeks

  8. Change in average fasting plasma glucose (FPG) after 4, 8, 12, and 16 weeks of treatment with investigational products compared to baseline

    Time frame: Baseline, 4 weeks, 8 weeks and 12 weeks and 16 weeks

  9. Change in Insulin, HOMA-β, HOMA-IR after 4, 8, 12, and 16 weeks of treatment with investigational products compared to baseline.

    Time frame: Baseline, 4 weeks, 8 weeks and 12 weeks and 16 weeks

07

Study locations

1 site
  • Samsung Medical Center
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2015, a primary completion of Feb 2017 and a completion of Feb 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2016
First posted
Oct 28, 2016
Start
Aug 2015
Primary completionActual
Feb 27, 2017
CompletionActual
Feb 27, 2017
Last update
Jun 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02947620
Responsible party
Sponsor
First posted
Oct 28, 2016
Start date
Aug 2015
Primary completion
Feb 27, 2017
Completion
Feb 27, 2017
Last update
Jun 18, 2023
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion